Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating
patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant
protein consisting of IL-3 linked to a toxic agent called DT. IL-3 attaches to IL-3 receptors
on tumor cells in a targeted way and delivers DT to kill them. Drugs used in chemotherapy
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving venetoclax and SL-401
with chemotherapy may be an effective treatment for patients with blastic plasmacytoid
dendritic cell neoplasm.